Increasing the evaluation of Mycoplasma and Ureaplasma infections in primary care: A quality improvement project
Abstract
BACKGROUND: Mycoplasma and Ureaplasma infections are frequently underdiagnosed and undertreated in primary care, contributing to adverse reproductive and genitourinary outcomes. Limited routine screening, diagnostic complexity, and variable provider awareness contribute to gaps in care.
LOCAL PROBLEM: In an academic primary care setting, patients presenting with genitourinary symptoms were infrequently evaluated for Mycoplasma and Ureaplasma.
METHODS: This quality improvement project was conducted in two academic family medicine clinics. Pre- and postintervention retrospective chart reviews assessed rates of testing and diagnosis among adult patients presenting with urethral or vaginal discharge, pelvic pain, and/or dysuria. Provider education and standardized evaluation and treatment algorithms were implemented.
INTERVENTIONS: An educational session was delivered and supported with emailed materials. Standardized algorithms outlining indications for testing and recommended treatments were integrated into clinical workflow.
RESULTS: During the study period, 519 patients presented with genitourinary symptoms. Recurrent symptoms consistent with Mycoplasma or Ureaplasma infection were identified in 205 patients (39.5%); however, 133 (64.9%) were not screened. Among the 72 patients (35.1%) who underwent diagnostic testing, 46 (63.9%) tested positive. Overall, 45 patients were diagnosed with Mycoplasma or Ureaplasma infections, including Mycoplasma hominis (26.7%), Ureaplasma…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 519 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.